Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)
NCT01530256 · CSL Behring · PHASE1/PHASE2 · terminated · last registry update 2021-02-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The trial was terminated in line with the endpoint committee charter.” | – | Registry record, CSL Behring |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL6 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-02-15Results posted on the registry: NYU Langone Health, Clazakizumab 25 mg + Clazakizumab 12.5 mg (NCT04343989)
- 2022-01-24Results posted on the registry: R-Pharm International, LLC, RPH-104 80 mg + Olokizumab 64 mg (NCT04380519)
- 2022-01-12Phase 3 first posted: R-Pharm, Olokizumab + Standard therapy (NCT05187793)
- 2021-12-06Results posted on the registry: CSL Behring, BMS-945429 Placebo + BMS-945429 (NCT01373151)
- 2021-12-03Results posted on the registry: CSL Behring, Placebo matching with BMS-945429 + Placebo matching with BMS-945429 (NCT01545050)
- 2021-12-03Also stopped (terminated): CSL Behring, Placebo matching with BMS-945429 + Placebo matching with BMS-945429 (NCT01545050)
- 2021-12-02Results posted on the registry: Cedars-Sinai Medical Center, Clazakizumab (NCT04348500)
- 2021-11-08Also stopped (withdrawn): R-Pharm, Olokizumab 64 mg + Placebo (NCT04452474)
- 2021-11-05Results posted on the registry: CSL Behring, Placebo matching BMS-945429 + BMS-945429 (NCT01490450)
- 2021-08-26Phase 3 first posted: Novo Nordisk A/S, Ziltivekimab B + Ziltivekimab C (NCT05021835)
- 2021-07-21Results posted on the registry: R-Pharm International, LLC, Olokizumab + Placebo (NCT02760433)
- 2021-05-11Results posted on the registry: CSL Behring, ALD518 + 0.9% saline (NCT01403064)
- 2021-05-11Also stopped (terminated): CSL Behring, ALD518 + 0.9% saline (NCT01403064)
- 2021-04-30Results posted on the registry: R-Pharm International, LLC, Olokizumab 64mg q4w + Olokizumab 64mg q2w (NCT02760407)
- 2021-04-19Results posted on the registry: CSL Behring, Clazakizumab + Placebo (Matching with Clazakizumab) (NCT02015520)
- 2021-04-19Also stopped (terminated): RECORDATI GROUP, Siltuximab (NCT04616586)
- 2021-04-19Also stopped (terminated): RECORDATI GROUP, Siltuximab (NCT04838860)
- 2020-11-05Phase 3 first posted: RECORDATI GROUP, Siltuximab (NCT04616586)
- 2020-10-30Results posted on the registry: R-Pharm International, LLC, Olokizumab + Placebo (NCT02760368)
- 2020-06-30Phase 3 first posted: R-Pharm, Olokizumab 64 mg + Placebo (NCT04452474)
- 2020-05-08Phase 3 first posted: R-Pharm International, LLC, RPH-104 80 mg + Olokizumab 64 mg (NCT04380519)
- 2020-04-01Phase 3 first posted: University Hospital, Ghent, Anakinra + Siltuximab (NCT04330638)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision